Literature DB >> 9863539

Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions.

N Sakata1, Y Imanaga, J Meng, Y Tachikawa, S Takebayashi, R Nagai, S Horiuchi, H Itabe, T Takano.   

Abstract

To better understand the role of advanced glycation end products (AGEs) in atherogenesis, we developed specific antibodies against different immunological epitopes of AGE structures, including Nepsilon-(carboxymethyl)lysine-protein adduct (CML) and a structure(s) other than CML (nonCML), and demonstrated the immunohistochemical localization of CML- and nonCML-epitopes in atherosclerotic lesions of human aorta, which were obtained at autopsy from 20 nondiabetic patients (12 males and eight females; mean age, 60.8+/-16.7 years). Monoclonal anti-CML antibody (6D12) recognized not only AGE-modified proteins, but also CML-modified proteins. On the other hand, polyclonal anti-nonCML antibody reacted to AGE-modified proteins, but not to CML-modified proteins. Both antibodies were unreactive to the early-stage products of glycation, including fructose-modified butyloxycarbonyl-lysine and fructose-epsilon-aminocaproic acid. Atherosclerotic lesions included diffuse intimal thickening (DIT), fatty streaks (FS), atherosclerotic plaques (AP) and complicated lesions. An immunohistochemical analysis showed both CML- and nonCML-epitopes to be found along the collagen fibers in DIT in subjects more than 40 years old, but not in subjects less than 40 years old. CML-epitopes accumulated mainly in the cytoplasm of macrophage/foam cells, while nonCML-epitopes accumulated exclusively in the extracellular spaces in FS. APs showed the CML-epitope stored macrophage/foam cells, and the accumulation of both CML- and nonCML-epitopes in the lipid-rich fibrous area. An immunohistochemical analysis with a monoclonal antibody against oxidized low density lipoprotein (FOH1a/DLH3) showed the presence of this antigen within the cytoplasm of the macrophage/foam cells in atherosclerotic lesions, which were also positive for the CML-epitopes. These findings thus suggest that the heterogeneous localization of AGEs in atherosclerotic lesions depends on their different epitopes, and that a close link, therefore, exists between the peroxidation of LDL and the formation of AGEs in atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863539     DOI: 10.1016/s0021-9150(98)00149-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Glycoxidation and diabetic complications: modern lessons and a warning?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes.

Authors:  Jolyane Meloche; Roxane Paulin; Audrey Courboulin; Caroline Lambert; Marjorie Barrier; Pierre Bonnet; Malik Bisserier; Mélanie Roy; Mark A Sussman; Mohsen Agharazii; Sébastien Bonnet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-16       Impact factor: 8.311

Review 3.  Antibody-based detection of advanced glycation end-products: promises vs. limitations.

Authors:  Ryoji Nagai; Jun-Ichi Shirakawa; Rei-Ichi Ohno; Kota Hatano; Hikari Sugawa; Shoutaro Arakawa; Kenta Ichimaru; Shoh Kinoshita; Noriyuki Sakata; Mime Nagai
Journal:  Glycoconj J       Date:  2016-07-15       Impact factor: 2.916

4.  Glucoselysine is derived from fructose and accumulates in the eye lens of diabetic rats.

Authors:  Rei-Ichi Ohno; Kenta Ichimaru; Seitaro Tanaka; Hikari Sugawa; Nana Katsuta; Shiori Sakake; Yu-Ki Tominaga; Ikuho Ban; Jun-Ichi Shirakawa; Yoshiki Yamaguchi; Emi Ito; Naoyuki Taniguchi; Ryoji Nagai
Journal:  J Biol Chem       Date:  2019-10-08       Impact factor: 5.157

Review 5.  Advanced glycation end products and vascular structure and function.

Authors:  Georgia Soldatos; Mark Emmanuel Cooper
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

6.  Age-dependent accumulation of advanced glycation endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine.

Authors:  A Georgescu; D Popov
Journal:  J Am Aging Assoc       Date:  2000-01

7.  Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries.

Authors:  Evanthia Diamanti-Kandarakis; Christina Piperi; Efstratios Patsouris; Penelope Korkolopoulou; Dimitrios Panidis; Leszek Pawelczyk; Athanasios G Papavassiliou; Antoni J Duleba
Journal:  Histochem Cell Biol       Date:  2007-01-05       Impact factor: 2.531

8.  Generation and characterization of monoclonal antibody against Advanced Glycation End Products in chronic kidney disease.

Authors:  Alessandra Becker Finco; Ricardo Andrez Machado-de-Ávila; Rayana Maciel; Juliana De Moura; Philippe Billiald; Andrea Emilia Marques Stinghen; Larissa M Alvarenga
Journal:  Biochem Biophys Rep       Date:  2016-03-23

9.  N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.

Authors:  Khaled A Ahmed; Sekaran Muniandy; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.